Cargando…

Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26

BACKGROUND: Chronic Fatigue Syndrome (CFS) studies from our laboratory and others described decreased natural killer cell cytotoxicity (NKCC) and elevated proportion of lymphocytes expressing the activation marker, dipeptidyl peptidase IV (DPPIV) also known as CD26. However, neither these assays nor...

Descripción completa

Detalles Bibliográficos
Autores principales: Fletcher, Mary A., Zeng, Xiao R., Maher, Kevin, Levis, Silvina, Hurwitz, Barry, Antoni, Michael, Broderick, Gordon, Klimas, Nancy G.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876037/
https://www.ncbi.nlm.nih.gov/pubmed/20520837
http://dx.doi.org/10.1371/journal.pone.0010817
_version_ 1782181647665332224
author Fletcher, Mary A.
Zeng, Xiao R.
Maher, Kevin
Levis, Silvina
Hurwitz, Barry
Antoni, Michael
Broderick, Gordon
Klimas, Nancy G.
author_facet Fletcher, Mary A.
Zeng, Xiao R.
Maher, Kevin
Levis, Silvina
Hurwitz, Barry
Antoni, Michael
Broderick, Gordon
Klimas, Nancy G.
author_sort Fletcher, Mary A.
collection PubMed
description BACKGROUND: Chronic Fatigue Syndrome (CFS) studies from our laboratory and others described decreased natural killer cell cytotoxicity (NKCC) and elevated proportion of lymphocytes expressing the activation marker, dipeptidyl peptidase IV (DPPIV) also known as CD26. However, neither these assays nor other laboratory tests are widely accepted for the diagnosis or prognosis of CFS. This study sought to determine if NKCC or DPPIV/CD26 have diagnostic accuracy for CFS. METHODS/RESULTS: Subjects included female and male CFS cases and healthy controls. NK cell function was measured with a bioassay, using K562 cells and (51)Cr release. Lymphocyte associated DPPIV/CD26 was assayed by qualitative and quantitative flow cytometry. Serum DPPIV/CD26 was measured by ELISA. Analysis by receiver operating characteristic (ROC) curve assessed biomarker potential. Cytotoxic function of NK cells for 176 CFS subjects was significantly lower than in the 230 controls. According to ROC analysis, NKCC was a good predictor of CFS status. There was no significant difference in NK cell counts between cases and controls. Percent CD2+ lymphocytes (T cells and NK cells) positive for DPPIV/C26 was elevated in CFS cases, but there was a decrease in the number of molecules (rMol) of DPPIV/C26 expressed on T cells and NK cells and a decrease in the soluble form of the enzyme in serum. Analyses by ROC curves indicated that all three measurements of DPPIV/CD26 demonstrated potential as biomarkers for CFS. None of the DPPIV/C26 assays were significantly correlated with NKCC. CONCLUSIONS: By ROC analysis, NKCC and three methods of measuring DPPIV/C26 examined in this study had potential as biomarkers for CFS. Of these, NKCC, %CD2+CD26+ lymphocytes and rMol CD26/CD2+ lymphocyte, required flow cytometry, fresh blood and access to a high complexity laboratory. Soluble DPPIV/C26 in serum is done with a standard ELISA assay, or with other soluble factors in a multiplex type of ELISA. Dipeptidyl peptidase IV on lymphocytes or in serum was not predictive of NKCC suggesting that these should be considered as non-redundant biomarkers. Abnormalities in DPPIV/CD26 and in NK cell function have particular relevance to the possible role of infection in the initiation and/or the persistence of CFS.
format Text
id pubmed-2876037
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-28760372010-06-02 Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26 Fletcher, Mary A. Zeng, Xiao R. Maher, Kevin Levis, Silvina Hurwitz, Barry Antoni, Michael Broderick, Gordon Klimas, Nancy G. PLoS One Research Article BACKGROUND: Chronic Fatigue Syndrome (CFS) studies from our laboratory and others described decreased natural killer cell cytotoxicity (NKCC) and elevated proportion of lymphocytes expressing the activation marker, dipeptidyl peptidase IV (DPPIV) also known as CD26. However, neither these assays nor other laboratory tests are widely accepted for the diagnosis or prognosis of CFS. This study sought to determine if NKCC or DPPIV/CD26 have diagnostic accuracy for CFS. METHODS/RESULTS: Subjects included female and male CFS cases and healthy controls. NK cell function was measured with a bioassay, using K562 cells and (51)Cr release. Lymphocyte associated DPPIV/CD26 was assayed by qualitative and quantitative flow cytometry. Serum DPPIV/CD26 was measured by ELISA. Analysis by receiver operating characteristic (ROC) curve assessed biomarker potential. Cytotoxic function of NK cells for 176 CFS subjects was significantly lower than in the 230 controls. According to ROC analysis, NKCC was a good predictor of CFS status. There was no significant difference in NK cell counts between cases and controls. Percent CD2+ lymphocytes (T cells and NK cells) positive for DPPIV/C26 was elevated in CFS cases, but there was a decrease in the number of molecules (rMol) of DPPIV/C26 expressed on T cells and NK cells and a decrease in the soluble form of the enzyme in serum. Analyses by ROC curves indicated that all three measurements of DPPIV/CD26 demonstrated potential as biomarkers for CFS. None of the DPPIV/C26 assays were significantly correlated with NKCC. CONCLUSIONS: By ROC analysis, NKCC and three methods of measuring DPPIV/C26 examined in this study had potential as biomarkers for CFS. Of these, NKCC, %CD2+CD26+ lymphocytes and rMol CD26/CD2+ lymphocyte, required flow cytometry, fresh blood and access to a high complexity laboratory. Soluble DPPIV/C26 in serum is done with a standard ELISA assay, or with other soluble factors in a multiplex type of ELISA. Dipeptidyl peptidase IV on lymphocytes or in serum was not predictive of NKCC suggesting that these should be considered as non-redundant biomarkers. Abnormalities in DPPIV/CD26 and in NK cell function have particular relevance to the possible role of infection in the initiation and/or the persistence of CFS. Public Library of Science 2010-05-25 /pmc/articles/PMC2876037/ /pubmed/20520837 http://dx.doi.org/10.1371/journal.pone.0010817 Text en Fletcher et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Fletcher, Mary A.
Zeng, Xiao R.
Maher, Kevin
Levis, Silvina
Hurwitz, Barry
Antoni, Michael
Broderick, Gordon
Klimas, Nancy G.
Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26
title Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26
title_full Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26
title_fullStr Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26
title_full_unstemmed Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26
title_short Biomarkers in Chronic Fatigue Syndrome: Evaluation of Natural Killer Cell Function and Dipeptidyl Peptidase IV/CD26
title_sort biomarkers in chronic fatigue syndrome: evaluation of natural killer cell function and dipeptidyl peptidase iv/cd26
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2876037/
https://www.ncbi.nlm.nih.gov/pubmed/20520837
http://dx.doi.org/10.1371/journal.pone.0010817
work_keys_str_mv AT fletchermarya biomarkersinchronicfatiguesyndromeevaluationofnaturalkillercellfunctionanddipeptidylpeptidaseivcd26
AT zengxiaor biomarkersinchronicfatiguesyndromeevaluationofnaturalkillercellfunctionanddipeptidylpeptidaseivcd26
AT maherkevin biomarkersinchronicfatiguesyndromeevaluationofnaturalkillercellfunctionanddipeptidylpeptidaseivcd26
AT levissilvina biomarkersinchronicfatiguesyndromeevaluationofnaturalkillercellfunctionanddipeptidylpeptidaseivcd26
AT hurwitzbarry biomarkersinchronicfatiguesyndromeevaluationofnaturalkillercellfunctionanddipeptidylpeptidaseivcd26
AT antonimichael biomarkersinchronicfatiguesyndromeevaluationofnaturalkillercellfunctionanddipeptidylpeptidaseivcd26
AT broderickgordon biomarkersinchronicfatiguesyndromeevaluationofnaturalkillercellfunctionanddipeptidylpeptidaseivcd26
AT klimasnancyg biomarkersinchronicfatiguesyndromeevaluationofnaturalkillercellfunctionanddipeptidylpeptidaseivcd26